AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01967628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Study NCT01967628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Study NCT04439604 — intervention group
Intervention type: OTHER
Intervention: regional ventilation monitoring
Description: regional ventilation monitoring
Study NCT04496622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV technique
Description: Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks
Study NCT04496622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration technique
Description: Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks
Study NCT03628053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: autologous cellular immunotherapy product
Study NCT03628053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blinatumomab
Description: bispecific CD19-directed CD3 T-cell engager
Study NCT03628053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotuzumab
Description: CD22-directed antibody-drug conjugate
Study NCT00635479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC device
Description: Vacuum Assisted Closure (VAC) device for surgical incision
Study NCT00635479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Gauze dressing for surgical incision
Study NCT01130285 — intervention group
Intervention type: GENETIC
Intervention: Lung Cancer Risk Test
Description: Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
Study NCT02963116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 IR tablet
Study NCT02963116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension
Study NCT02963116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin tablet
Study NCT01075412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F18]Fluorothymidine
Description: FLT PET scan 5 mCi (+/- 10%)
Study NCT04178759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Laparoscopic or open approach liver resection where at least 1 segment is removed
Study NCT04178759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Laparoscopic or open approach liver resection where at least 1 segment is removed
Study NCT03962738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT03962738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03962738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02409849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide lar
Study NCT02431091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
Study NCT02431091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
Study NCT02520323 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Study NCT02520323 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Study NCT02520323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Study NCT00530283 — intervention group
Intervention type: OTHER
Intervention: PET-CT
Study NCT02243254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose remifentanil
Description: high dose remifentanil
Study NCT02243254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high dose remifentanil
Description: high dose remifentanil
Study NCT02243254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: intravenous ibuprofen
Study NCT02243254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose remifentanil
Description: low dose remifentanil
Study NCT02243254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose remifentanil
Description: low dose remifentanil
Study NCT04579562 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is observational, non-interventional study
Study NCT04185753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
Description: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
Study NCT03750578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality goggle (Oculus Rift ® Helmet)
Description: as described
Study NCT03807804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLCM051
Description: HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
Study NCT01242267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide+Melphalan +Bortezomib+stem cell transplant
Description: Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
Study NCT02887404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine surgery analgesic pathway
Description: Enhanced pain management care
Study NCT02887404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of pain management care
Study NCT01012102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
Study NCT01012102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
Study NCT01012102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
Study NCT01012102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
Study NCT01012102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
Study NCT01012102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
Study NCT03048539 — intervention group
Intervention type: PROCEDURE
Intervention: Transoral endoscopic thyroidectomy
Description: This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
Study NCT03747211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: High Intensity Interval Training (HIIT)
Study NCT02870049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inreach strategy
Description: Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
Study NCT02870049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach strategy
Description: Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
Study NCT02870049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Inreach and Outreach strategies
Description: Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
Study NCT02870049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care: FIT kit delivery as part of usual care
Study NCT02327052 — intervention group
Intervention type: OTHER
Intervention: No intervention was performed.
Description: No intervention was performed.
Study NCT04277520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal therapy
Description: Different types of instrumentation motions during root canal therapy
Study NCT03640598 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ilioinguinal/iliohypogastric nerve blocks
Description: The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
Study NCT03640598 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Erector spinae nerve block
Description: The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
Study NCT01504165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 2000mg
Description: A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
Study NCT01504165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide 1000mg
Description: A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
Study NCT01504165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide > 1000mg and up to 2000mg
Description: A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
Study NCT00817882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individually targeted vocational rehabilitation
Description: individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain
Study NCT00817882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine back pain rehabilitation
Description: routine back pain rehabilitation Maximum of 25 patients with low back pain
Study NCT01427465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Consult
Study NCT01427465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Prevention Program Using Positive Image
Description: Control - Standard of Care
Study NCT01427465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Newsletter
Study NCT01427465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prevention Program Using Positive Image
Description: Parent Letter
Study NCT03341975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth
Description: To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
Study NCT01382797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 37
Description: Capsules for oral administration
Study NCT01382797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study NCT04514120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AJESS scoring process
Description: We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
Study NCT02127671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAL intervention
Study NCT02127671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT00801645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
Study NCT04213105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 60 mg (1ml) only once,on the first day.
Study NCT04213105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: subcutaneous injection of 60 mg (1ml)only once,on the first day
Study NCT02821923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E967-Xylitol
Description: 24g xylitol/d
Study NCT02821923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E968-Erythritol
Description: 36g erythritol/d
Study NCT02663453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multicomponent lipid emulsion
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
Study NCT02663453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pure soybean oil lipid emulsion
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Human anti-PD-1 IgG4 kappa monoclonal antibody
Study NCT03169764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters
Study NCT03169764 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SRBT)
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\]
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen (CEA) vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 (HER2) vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 (MUC1) vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Ras yeast vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03169764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study NCT00995475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Study NCT00995475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Study NCT00995475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00995475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00336219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Symptom Assessment after treatment with Pantoprozole 40 mg
Study NCT03502291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study one: LAIV + Inoculation
Description: Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
Study NCT03502291 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Study one: Placebo + Inoculation
Description: Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
Study NCT03502291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study two: Inoculation + LAIV
Description: Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
Study NCT03502291 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Study two: Inoculation + placebo
Description: Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
Study NCT02800070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Alpha-gal A transduced stem cells
Study NCT01390766 — intervention group
Intervention type: DRUG
Intervention: Azathioprine
Study NCT04053647 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study NCT02088970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinking
Description: The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.